Please select the option that best describes you:
Topics:
Thoracic Malignancies • Medical Oncology
In patients with resected stage II-III NSCLC, who completed adjuvant carboplatin and pemetrexed and are PD-L1 high, which immunotherapy would you offer?
The patient is driver mutation negative. Would you prefer atezolizumab per IMPOWER010 or Pembrolizumab per KN091?